

US COMMERCIAL PHARMACEUTICAL LEADER IAN WISENBERG APPOINTED NON-EXECUTIVE DIRECTOR

Adelaide, Australia, 18 September 2024: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the appointment of Mr Ian Wisenberg to the LBT Board as Non-Executive Director effective 1 October 2024.

Residing in Park City, Utah, Mr Wisenberg has held C-suite leadership positions with global life science and pharmaceutical companies, as well as an advisor to the industry on growth strategies and M&A. In recent years he led the acquisition of Bridgewest Groups first biologics manufacturing facility and operation from Pfizer in Adelaide, Australia. After the closing of the transaction, he was appointed Chief Executive Officer of the operating entity, BioCina Pty Ltd., and was responsible for transitioning the operations from being fully integrated within Pfizer to a standalone Contract Development and Manufacturing Organisation (CDMO), serving Pharma and Biotech from process development through to commercial manufacturing.

Other Private Equity and M&A activity includes the sale of 80% of BioDuro to Advent International and the original acquisition of BioDuro from Pharmaceutical Development Corp, the asset acquisition from PharmaForm that led to the formation of Formex LLC, a premier provider in the contract pharmaceutical formulation and clinical manufacturing service sectors, and the sale of Molecular Response to Crown Biosciences.

Mr Wisenberg has an extensive global network of pharmaceutical and large biotechnology companies with that includes specific relationships in drug manufacturing.

In addition, after serving three years on the Board, Mr Brian O'Dwyer will not stand for re-election at the Company's Annual General Meeting to be held in November due to increasing executive responsibilities in his role as Chief Executive Officer Q2 Solutions & Clinical FSP at IQVIA. He will retire at the Company's AGM.

Commenting on the board changes, LBT's Independent Non-Executive Chair Ms Rebecca Wilson said: *"We are pleased to welcome Ian to the Board of LBT at a time of momentum in pursuing opportunities with APAS Independence in providing environmental monitoring in pharmaceutical manufacturing globally."*

"Ian brings a strong commercial and M&A skillset with both executive and non-executive leadership roles across the pharmaceutical and life science sectors, and with specific experience working within drug manufacturing."

"We look forward to benefiting from his experience and deep relevant network as we pursue our growth strategy rapidly."

"I'd like to thank Brian for his contributions to the Board over these last three years, at a time of significant change. Brian provided important guidance to the Board and executive team on both clinical and pharmaceutical markets given his executive experience. We have appreciated his commitment to LBT over this last year in particular where his executive role has expanded significantly."

Incoming Non-Executive Director Mr Wisenberg said: *"The pivot into the pharmaceutical market for LBT has been an important one and is how I was first introduced to the Company while establishing BioCina. The AI technology is groundbreaking and differentiating that has the potential to set a new standard for environmental monitoring in drug manufacturing. I will be hands-on in utilising my global network of customers and partners that may benefit from the APAS technology."*

Mr Wisenberg's appointment will be considered by the Company's shareholders at its AGM in November.

Approved for release by the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com